MSH2 and adenocarcinoma: Another report on MSH2-deficient prostate cancer found that 8% (7/91) of adenocarcinomas with a Gleason score of 9–10 are MSH2-deficient compared to 0.4% (5/1,042) of adenocarcinomas with other scores [24].